Rottlerin activates AMPK possibly through LKB1 in vascular cells and tissues
- PMID: 18789895
- DOI: 10.1016/j.bbrc.2008.09.007
Rottlerin activates AMPK possibly through LKB1 in vascular cells and tissues
Abstract
AMP-activated protein kinase (AMPK) is a cellular energy sensor involved in multiple cell signaling pathways that has become an attractive therapeutic target for vascular diseases. It is not clear whether rottlerin, an inhibitor of protein kinase Cdelta, activates AMPK in vascular cells and tissues. In the present study, we have examined the effect of rottlerin on AMPK in vascular smooth muscle cells (VSMCs) and isolated rabbit aorta. Rottlerin reduced cellular ATP and activated AMPK in VSMCs and rabbit aorta; however, inhibition of PKCdelta by three different methods did not activate AMPK. Both VSMCs and rabbit aorta expressed the upstream AMPK kinase LKB1 protein, and rottlerin-induced AMPK activation was decreased in VSMCs by overexpression of dominant-negative LKB1, suggesting that LKB1 is involved in the upstream regulation of AMPK stimulated by rottlerin. These data suggest for the first time that LKB1 mediates rottlerin-induced activation of AMPK in vascular cells and tissues.
Similar articles
-
Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase.Cell Metab. 2005 Jul;2(1):9-19. doi: 10.1016/j.cmet.2005.05.009. Cell Metab. 2005. PMID: 16054095
-
SIRT1 promotes proliferation and prevents senescence through targeting LKB1 in primary porcine aortic endothelial cells.Circ Res. 2010 Apr 30;106(8):1384-93. doi: 10.1161/CIRCRESAHA.109.215483. Epub 2010 Mar 4. Circ Res. 2010. PMID: 20203304
-
Rottlerin: an inappropriate and ineffective inhibitor of PKCdelta.Trends Pharmacol Sci. 2007 Sep;28(9):453-8. doi: 10.1016/j.tips.2007.07.003. Epub 2007 Aug 10. Trends Pharmacol Sci. 2007. PMID: 17692392 Review.
-
Nifedipine inhibits vascular smooth muscle cell proliferation and reactive oxygen species production through AMP-activated protein kinase signaling pathway.Vascul Pharmacol. 2012 Jan-Feb;56(1-2):1-8. doi: 10.1016/j.vph.2011.06.001. Epub 2011 Jun 25. Vascul Pharmacol. 2012. PMID: 21708289
-
The AMP-activated protein kinase pathway--new players upstream and downstream.J Cell Sci. 2004 Nov 1;117(Pt 23):5479-87. doi: 10.1242/jcs.01540. J Cell Sci. 2004. PMID: 15509864 Review.
Cited by
-
Rottlerin and cancer: novel evidence and mechanisms.ScientificWorldJournal. 2012;2012:350826. doi: 10.1100/2012/350826. Epub 2012 Jan 4. ScientificWorldJournal. 2012. PMID: 22272173 Free PMC article. Review.
-
Tumor Suppressor Serine/Threonine Kinase LKB1 Expression, Not Kinase Activity, Increased in the Vascular Smooth Muscle Cells and Neointima in the Rat Carotid Artery Injury Model.Korean Circ J. 2010 Nov;40(11):552-7. doi: 10.4070/kcj.2010.40.11.552. Epub 2010 Nov 30. Korean Circ J. 2010. PMID: 21217931 Free PMC article.
-
Rottlerin induces Wnt co-receptor LRP6 degradation and suppresses both Wnt/β-catenin and mTORC1 signaling in prostate and breast cancer cells.Cell Signal. 2014 Jun;26(6):1303-9. doi: 10.1016/j.cellsig.2014.02.018. Epub 2014 Mar 6. Cell Signal. 2014. PMID: 24607787 Free PMC article.
-
Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling.PLoS One. 2009 Sep 22;4(9):e7124. doi: 10.1371/journal.pone.0007124. PLoS One. 2009. PMID: 19771169 Free PMC article.
-
Rottlerin increases cardiac contractile performance and coronary perfusion through BKCa++ channel activation after cold cardioplegic arrest in isolated hearts.Circulation. 2011 Sep 13;124(11 Suppl):S55-61. doi: 10.1161/CIRCULATIONAHA.110.012112. Circulation. 2011. PMID: 21911819 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources